InMed Demonstrates Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions

Leading cannabinoid researcher, developer and manufacturer, InMed Pharmaceuticals (Nasdaq: INM) has demonstrated the anti-inflammatory potential of rare cannabinoids in skin conditions.

The company has sponsored a peer-reviewed scientific study: “Rare phytocannabinoids exert anti-inflammatory effects on human keratinocytes via the endocannabinoid system and MAPK signalling pathway” which has been been published in the International Journal of Molecular Sciences.

InMed’s share price rose more than 40% in intra-day trading following the news.

Highlights

• The company-sponsored study investigated the anti-inflammatory effects of the rare cannabinoids, cannabichromene (CBC), Δ9-tetrahydrocannabivarin (THCV), cannabigerol (CBG) and cannabigerolic acid (CBGA) on inflamed human keratinocytes.
• The study demonstrated the anti-inflammatory effects of rare cannabinoids and their potential application for the treatment of skin conditions such as atopic dermatitis, psoriasis, pruritus, and acne.
• The rare cannabinoids significantly blocked inflammation by reducing the release of tested pro-inflammatory interleukins.

InMed’s study was conducted in collaboration with the company’s scientific advisor, Dr. Mauro Maccarrone, Professor and Chair of Biochemistry at the Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Italy.